Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Overall, we expect Bristol-Myers Squibb’s oncology revenue to jump from nearly $6.8 billion in 2016 to more than $12 billion by the end of our forecast period, implying annual average growth of nearly 8.7%. Even in 2016, Opdivo outperformed Bristol-Myers Squibb’s remaining cancer drug portfolio. However, there are competitive challenges on the horizon and there is going to be some degree of uncertainty in the lung cancer treatment landscape. In fact, Opdivo lost some share in the lung cancer market in the first quarter of 2017.

Source: Forbes June 27, 2017 15:22 UTC